Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

President Trump at the White House - Washington

President Donald Trump shakes hands with Pfizer CEO Albert Bourla, right, during an announcement in the Oval Office at the White House, Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

President Trump at the White House - Washington

Pfizer CEO Albert Bourla, left, and President Donald Trump during an announcement in the Oval Office at the White House, Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

President Donald Trump speaks during an announcement of a drug-pricing deal with Pfizer in the Oval Office of the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

President Donald Trump departs at the end of an announcement of a drug-pricing deal with Pfizer in the Oval Office of the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

President Donald Trump departs at the end of an announcement of a drug-pricing deal with Pfizer in the Oval Office of the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

Food and Drug Administration Commissioner Marty Makary stands near a sign on lowering drug pricing for Americans during the announcement of a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

President Donald Trump speaks alongside, from left, Vice President JD Vance, Director of Medicare and Deputy Administrator of CMS Chris Klomp, Pfizer CEO Albert Bourla, Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary announce a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

Centers for Medicare and Medicaid Services Administrator Mehmet Oz, President Donald Trump, and Food and Drug Administration Commissioner Marty Makary take part in the announcement of a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

Vice President JD Vance looks on during the announcement of a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

Health and Human Services Secretary Robert F. Kennedy Jr. looks on during the announcement of a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

President Donald Trump announces a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. announce a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

The right hand of President Donald Trump is seen as he announces a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

Director of Medicare and Deputy Administrator of CMS Chris Klomp takes part in an announcement of a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

Health and Human Services Secretary Robert F. Kennedy Jr. looks on during the announcement of a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

From left, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, Pfizer CEO Albert Bourla, President Donald Trump, and Food and Drug Administration Commissioner Marty Makary announce a drug-pricing deal in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

From left, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, Pfizer CEO Albert Bourla, President Donald Trump, and Food and Drug Administration Commissioner Marty Makary announce a drug-pricing deal in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

Director of Medicare and Deputy Administrator of CMS Chris Klomp and Pfizer CEO Albert Bourla take part in an announcement of a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

President Donald Trump announces a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

President Donald Trump stands near a sign on lowering drug prices for Americans as he announces a drug-pricing deal with Pfizer in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

White House

Pfizer CEO Albert Bourla speaks alongside, from left, Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare and Medicaid Services Administrator Mehmet Oz, President Donald Trump, and Food and Drug Administration Commissioner Marty Makary in the Oval Office at the White House Sept. 30, 2025. Photo by Francis Chung/Pool/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

The civil parties to be prosecuted in criminal proceedings Ursula Von der Leyen and Albert Bourla (Pfizer). The case of corruption complaints against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, on Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liège. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

Florian Philippot is a civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer) in criminal proceedings. The case of the complaints for corruption against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liege, Belgium. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

Florian Philippot is a civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer) in criminal proceedings. The case of the complaints for corruption against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liege, Belgium. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

The civil parties to be prosecuted in criminal proceedings Ursula Von der Leyen and Albert Bourla (Pfizer). The case of corruption complaints against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, on Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liège. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

Florian Philippot is a civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer) in criminal proceedings. The case of the complaints for corruption against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liege, Belgium. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

En photo Les parties civile à poursuivre au pénal Ursula Vonderleyen et Albert Bourla (Pfizer). Le dossier des plaintes pour corruption à l’encontre de la présidente de la Commission européenne, Ursula von der Leyen, et du PDG de Pfizer, Albert Bourla, revient de nouveau, vendredi 6 décembre 2024 à 14h, devant la Chambre du conseil du tribunal de première instance de Liège. - In photo The civil parties to be prosecuted in criminal proceedings Ursula Vonderleyen and Albert Bourla (Pfizer). The case of corruption complaints against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, on Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liège. Photo Philippe BOURGUET / bePress Photo Agency/bppa

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

The case of corruption complaints against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, on Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liège. hoto by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

Florian Philippot is a civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer) in criminal proceedings. The case of the complaints for corruption against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liege, Belgium. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

Florian Philippot is a civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer) in criminal proceedings. The case of the complaints for corruption against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liege, Belgium. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

Isabelle Duchateau, civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer). The case of corruption complaints against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, on Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liège. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

Florian Philippot is a civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer) in criminal proceedings. The case of the complaints for corruption against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liege, Belgium. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

The Belgian lobbyist, Frederic Baldan, is a civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer). The case of corruption complaints against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, on Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liège. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

Florian Philippot is a civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer) in criminal proceedings. The case of the complaints for corruption against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liege, Belgium. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

Pfizergate - Criminal Complaint Referral To The Liege Correctional Court

Florian Philippot is a civil party to prosecute Ursula Von der Leyen and Albert Bourla (Pfizer) in criminal proceedings. The case of the complaints for corruption against the President of the European Commission, Ursula von der Leyen, and the CEO of Pfizer, Albert Bourla, returns again, Friday, December 6, 2024 at 2 p.m., before the Council Chamber of the Court of First Instance of Liege, Belgium. Photo by Philippe BOURGUET /BePress/ABACAPRESS.COM

E

CHINA-BEIJING-HE LIFENG-PFIZER-CHAIRMAN-MEETING (CN)

(240325) -- BEIJING, March 25, 2024 (Xinhua) -- Chinese Vice Premier He Lifeng, also a member of the Political Bureau of the Communist Party of China Central Committee, meets with Pfizer chairman Albert Bourla attending the China Development Forum 2024 in Beijing, capital of China, March 25, 2024. (Xinhua/Yue Yuewei)

E

(CIIE) CHINA-SHANGHAI-CIIE-BUSINESS-OPPORTUNITY (CN)

(231108) -- SHANGHAI, Nov. 8, 2023 (Xinhua) -- This photo shows the Pfizer booth at the 6th China International Import Expo (CIIE) in east China's Shanghai, Nov. 8, 2023. The 6th China International Import Expo (CIIE), which has attracted over 3,400 exhibitors globally, showcases China's new development paradigm and builds a broad platform for global business to gain more opportunities in the world's most promising market. (Xinhua/Li Mengjiao)

E

Emmanuel Macron receives Albert Bourla CEO of Pfizer - Paris

Reda Guiha Country President, Pfizer France and Albert Bourla CEO of Pfizer at Elysee Palace in Paris, France on May 15, 2023. as part of the 6th edition of the "Choose France" Business Summit, Photo by Stephane Lemouton/Pool/ABACAPRESS.COM

E

Emmanuel Macron receives Albert Bourla CEO of Pfizer - Paris

Reda Guiha Country President, Pfizer France and Albert Bourla CEO of Pfizer at Elysee Palace in Paris, France on May 15, 2023. as part of the 6th edition of the "Choose France" Business Summit, Photo by Stephane Lemouton/Pool/ABACAPRESS.COM

E

Investment deals worth 9.8 bln USD signed at Shanghai Global Investment Promotion Conference

STORY: Investment deals worth 9.8 bln USD signed at Shanghai Global Investment Promotion Conference DATELINE: April 7, 2023 LENGTH: 00:01:19 LOCATION: SHANGHAI, China CATEGORY: ECONOMY SHOTLIST: 1. various of the 2023 Shanghai Global Investment Promotion Conference 2. SOUNDBITE 1 (English): JEAN CHRISTOPHE POINTEAU, President of Pfizer China 3. SOUNDBITE 2 (English): DEBAJIT DAS, Chairman of Shanghai Das Brothers AI Technology Co., Ltd. 4. SOUNDBITE 3 (Chinese): SIU WING CHU, Chief Executive Officer of Savills China STORYLINE: Twenty-six investment projects were signed Thursday at the 2023 Shanghai Global Investment Promotion Conference, with a total contract value of 67.4 billion yuan (about 9.8 billion U.S. dollars). The one-day conference was attended by many global companies, demonstrating the city's strong appeal as an investment destination. SOUNDBITE 1 (English): JEAN CHRISTOPHE POINTEAU, President of Pfizer China "Shanghai is a very important city. It is one of the top leading cities of China. S

E

1st batch of Pfizer COVID-19 vaccine arrives in Japan

NARITA, Japan, Feb. 12 Kyodo - Photo taken from a Kyodo News helicopter on Feb. 12, 2021, shows cargo being unloaded at Narita airport near Tokyo from an airplane that transported from Brussels the first batch to arrive in Japan of the coronavirus vaccine developed by U.S. pharmaceutical giant Pfizer Inc.

E

1st batch of Pfizer COVID-19 vaccine arrives in Japan

NARITA, Japan, Feb. 12 Kyodo - Cargo is unloaded at Narita airport near Tokyo on Feb. 12, 2021, from an airplane that transported from Brussels the first batch to arrive in Japan of the coronavirus vaccine developed by U.S. pharmaceutical giant Pfizer Inc.

E

Pfizer to donate antifungal drug to 5 southern Africa nations

NEW YORK, United States - Pfizer Inc. Chief Executive Hank McKinnell announces at a news conference at the United Nations headquarters June 6 the company will donate its antifungal drug Diflucan to AIDS patients in five southern African countries in a program that it said would eventually benefit 50 poor countries suffering from the HIV/AIDS epidemic.

E

Japan permits manufacturing, import of Viagra

Leslie Robert Patterson, country manager of Pfizer Pharmaceuticals Inc., meets the press in Tokyo on Jan. 25 after the Tokyo-based affiliate of Pfizer Inc. of the United States obtained permission from Japan's Health and Welfare Ministry to manufacture and import the anti-impotence drug Viagra.

E

(CIIE) CHINA-SHANGHAI-CIIE-EXHIBITION (CN)

(221105) -- SHANGHAI, Nov. 5, 2022 (Xinhua) -- The booth of Pfizer is seen at the medical equipment and health care products exhibition area of the fifth China International Import Expo (CIIE) at the National Exhibition and Convention Center (Shanghai) in east China's Shanghai, Nov. 5, 2022. The fifth CIIE is scheduled on Nov. 5-10 in China's economic hub Shanghai. (Xinhua/Ding Ting)

E

Spanish Hipra vaccine to test its fourth dose

STORY: Spanish Hipra vaccine to test its fourth dose DATELINE: Sept. 1, 2022 LENGTH: 00:01:34 LOCATION: Madrid CATEGORY: HEALTH SHOTLIST: 1. various of HIPRA Laboratories 2. various of people at hospital STORYLINE: The Spanish pharmaceutical company HIPRA has announced that it will start a clinical trial in 10 hospitals at the end of this summer to study the effectiveness of its vaccine as a possible fourth dose to protect against COVID-19. Each of the 10 hospitals will test 200 volunteers, who have previously received 3 doses of a different vaccine (such as Pfizer-BioNTech), to discover the immune response and evaluate the safety of the HYPRA vaccine as a second 'booster' dose. The HYPRA vaccine is currently pending approval by the European Medicines Agency (EMA) in order to be marketed. The hospitals will start the trial once permission has been received from the Spanish Agency for Medicines and Health Products (AEMPS) and the Ethics Committee for Research with Medicines of the Hospital Clinic d

E

Israel begins vaccinating children under 5 against COVID-19

STORY: Israel begins vaccinating children under 5 against COVID-19 DATELINE: Aug. 3, 2022 LENGTH: 0:01:26 LOCATION: Jerusalem CATEGORY: HEALTH SHOTLIST: 1. various of a four-year old before and after receiving COVID-19 vaccine STORYLINE: A nationwide vaccination campaign against COVID-19 for children aged six months to five years was launched in Israel on Sunday. The vaccination will provide children "with an important protection layer against serious illness and post-COVID symptoms," said a statement issued by the Israeli Ministry of Health on Sunday evening. The vaccine is especially recommended for children at risk of severe COVID-19 illness due to underlying health conditions that impair the immune system, the ministry noted. The shots will either be three doses of the Pfizer vaccine or two doses of the Moderna vaccine, said the ministry. Vaccination for children under the age of five was approved by the ministry's Director General Nachman Ash earlier this month, following a recommendation by a pan

E

07000000-HTH- NEPAL- KATHMANDU- PAEDIATRIC VACCINE ROLL OUT

A secondary level student at a local school in Nepali capital Kathmandu reacts while a paramedic admisters dosage of Pfizer-BioNTech manufactured anti-COVID vaccine. Nepal from 23rd June has rolled out vaccination campaign targeting the population (especially students) aged between 5 years to 12 years with the US donated paediatric vaccines.

E

07000000-HTH- NEPAL- KATHMANDU- PAEDIATRIC VACCINE ROLL OUT

A secondary level student at a local school in Nepali capital Kathmandu reacts while a paramedic admisters dosage of Pfizer-BioNTech manufactured anti-COVID vaccine. Nepal from 23rd June has rolled out vaccination campaign targeting the population (especially students) aged between 5 years to 12 years with the US donated paediatric vaccines.

E

07000000-HTH- NEPAL- KATHMANDU- PAEDIATRIC VACCINE ROLL OUT

A secondary level student at a local school in Nepali capital Kathmandu reacts while a paramedic admisters dosage of Pfizer-BioNTech manufactured anti-COVID vaccine. Nepal from 23rd June has rolled out vaccination campaign targeting the population (especially students) aged between 5 years to 12 years with the US donated paediatric vaccines.